Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

305 results found

2025 ∙ Maggi, S. Fulop, T. De Vita, E. Limongi, F. Pizzol, D. Di Gennaro, F. Veronese, N.

Association between vaccinations and risk of dementia: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Herpes zoster
  • Tetanus
  • Diphtheria
  • Pertussis
  • Influenza
  • Pneumococcal disease
  • Poliomyelitis
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Vink, K. Kusters, J. Wallinga, J.

Chrono-optimizing vaccine administration: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Influenza
  • Hepatitis B
  • Hepatitis A
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Fletcher, M. A. Okasha, O. Baay, M. Syrochkina, M. Hayford, K.

Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022

  • All age groups
  • Pneumococcal disease
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Cao, B. K. Hanifa, R. S. Nguyen, T. P. Postma, M. J. van der Schans, J.

Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review

  • South-East Asia
  • Western Pacific
  • Adults
  • Older adults
  • Influenza
  • COVID-19
  • Pneumococcal disease
  • Varicella
  • Pertussis
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Peng, R. Zhang, T. Dunne, E. M. Xu, Z. Sun, A. Cheng, J. Yang, J. Zhao, G.

Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis

  • Western Pacific
  • China
  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Dunne, E. M. Hong, L. Althouse, B. M. Hayford, K. Jodar, L. Gessner, B. D. Theilacker, C.

Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Bulkhi, A. Khadawardi, H. A. Dairi, M. S. Alwafi, H. Alim, H. M. Turkistani, Y. A. Almoallim, H. M. Alghamdi, I. A. Alqashqri, H. S. Obaid, M. S. Alkhotani, A. M. A. Alhazmi, A. S. H. Adly, H. M. Zaini, R. Abdulkhaliq, A. A. Saleh, S. A. K. Hariri, N. H. Khan, A. A. Alamri, F. A. Garout, M. A.

Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: A systematic review and meta-analysis

  • Adults
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Chang, C. Y. Nasreen, S. Sadarangani, M. Aquino, K. Cragg, J. J. Marra, F.

Effectiveness of vaccine dosing schedules for pneumococcal invasive disease in children: A systematic review and meta-analysis

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Nimpa, M. M. Ntambue, A. Ngandu, C. Danovaro-Holliday, M. C. Bita Fouda, A. Cikomola, A. M. W. Mukendi, J. C. Mwamba, D. Aluma, A. D. L. Yapi, M. D. Nikiema, J. B. Hama Sambo, B. Ishoso, D. K.

Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review

  • Africa
  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Dai, Q. Dong, Y. Wu, J. Peng, Q.

Efficacy, immunogenicity, and safety of pneumococcal conjugate vaccine in children: a systematic review and meta-analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...